AbCellera Biologics Inc. 8-K

What Happened

• AbCellera Biologics Inc. (ABCL) filed a Form 8-K on February 24, 2026 to announce its financial and operational results for the year ended December 31, 2025. The company furnished a press release with the results (Exhibit 99.1) and a corporate presentation to be used on its earnings call the same day (Exhibit 99.2). The Form 8-K was signed by CEO Carl L. G. Hansen, Ph.D.

Key Details

• Filing date: February 24, 2026; fiscal period covered: year ended December 31, 2025.
• Exhibit 99.1: Press release announcing results; Exhibit 99.2: Corporate presentation for the Feb 24, 2026 earnings call.
• The disclosures were furnished under Item 2.02 (results) and Item 7.01 (Regulation FD disclosure) and are expressly noted as furnished—not “filed”—under the Exchange Act.
• CEO who signed the filing: Carl L. G. Hansen, Ph.D.

Why It Matters

• This 8-K signals that AbCellera has released its full-year 2025 earnings and related materials; investors should review the press release and presentation for revenue, earnings, guidance, and operational updates.
• The Regulation FD notice and furnished presentation indicate the company is disclosing information publicly via its earnings call; because the materials are furnished (not filed), they are not subject to the heightened liability under Section 18 of the Exchange Act.
• Retail investors should read the included exhibits and listen to the earnings call to see material items (revenue, net income/loss, cash position, and any guidance) that could affect ABCL stock.